肾素-血管紧张素系统抑制剂能否预防重症新型冠状病毒肺炎？ - Suppr

Could Renin-Angiotensin System Inhibitors Be Protective From Severe COVID-19?

作者信息

Carey Robert M

机构信息

From the Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville.

出版信息

Hypertension. 2021 Mar 3;77(3):843-845. doi: 10.1161/HYPERTENSIONAHA.120.16800. Epub 2021 Feb 10.

DOI:10.1161/HYPERTENSIONAHA.120.16800

PMID:33566689

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7884239/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b231/7884239/c32b8600d40f/hyp-77-843-g001.jpg

相似文献

Could Renin-Angiotensin System Inhibitors Be Protective From Severe COVID-19?肾素-血管紧张素系统抑制剂能否预防重症新型冠状病毒肺炎？

Hypertension. 2021 Mar 3;77(3):843-845. doi: 10.1161/HYPERTENSIONAHA.120.16800. Epub 2021 Feb 10.

Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.抗高血压药物的停用对因严重急性呼吸综合征冠状病毒 2 住院患者结局的影响。

Hypertension. 2021 Jul;78(1):165-173. doi: 10.1161/HYPERTENSIONAHA.121.17328. Epub 2021 Jun 9.

Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.关于在新冠疫情背景下成人和儿童使用肾素-血管紧张素系统降压阻滞剂的考量

Bol Med Hosp Infant Mex. 2020;77(5):274-281. doi: 10.24875/BMHIM.20000158.

Increased Mortality in Antecedent Combined Renin-Angiotensin System Inhibitors and Antiplatelets Compared With Antiplatelets Alone in Hospitalized Patients With COVID-19.与单独使用抗血小板药物相比，住院 COVID-19 患者中联合使用肾素-血管紧张素系统抑制剂和抗血小板药物会增加死亡率。

Am J Ther. 2021 Jun 25;28(5):e587-e590. doi: 10.1097/MJT.0000000000001410.

Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.在2019冠状病毒病大流行期间，使用血管紧张素II受体阻滞剂或血管紧张素转换酶抑制剂治疗高血压。

Expert Rev Cardiovasc Ther. 2021 Jan;19(1):99-100. doi: 10.1080/14779072.2021.1842050. Epub 2020 Nov 12.

Long-term effects of discontinuing renin-angiotensin system inhibitors in COVID-19.停用肾素-血管紧张素系统抑制剂对新型冠状病毒肺炎的长期影响。

Respirology. 2022 Sep;27(9):788-790. doi: 10.1111/resp.14306. Epub 2022 Jun 7.

The Role of the Renin-Angiotensin System in Severe Acute Respiratory Syndrome-CoV-2 Infection.肾素-血管紧张素系统在严重急性呼吸综合征冠状病毒2型感染中的作用

Blood Purif. 2021;50(2):263-267. doi: 10.1159/000507914. Epub 2020 Apr 28.

COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?新型冠状病毒肺炎、高血压与肾素-血管紧张素-醛固酮系统抑制剂：小题大做还是亟待解决的实际问题？

J Clin Hypertens (Greenwich). 2020 Nov;22(11):1984-1986. doi: 10.1111/jch.14045. Epub 2020 Sep 20.

Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.SARS-CoV-2 与肾素血管紧张素系统相互作用的临床意义：美国心脏病学会评论专题周报。

J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.

Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？

Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.

引用本文的文献

Hypertension Update: A Reflection of the Past Decade.高血压最新进展：过去十年的回顾

Hypertension. 2021 Dec;78(6):1670-1673. doi: 10.1161/HYPERTENSIONAHA.121.18596. Epub 2021 Nov 10.

本文引用的文献

Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.抗高血压药物与 COVID-19 风险：一项涉及 200 万高血压患者的队列研究。

Hypertension. 2021 Mar 3;77(3):833-842. doi: 10.1161/HYPERTENSIONAHA.120.16314. Epub 2021 Jan 11.

Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂与严重急性呼吸综合征冠状病毒 2 感染风险：系统评价和荟萃分析。

Hypertension. 2020 Nov;76(5):1563-1571. doi: 10.1161/HYPERTENSIONAHA.120.15989. Epub 2020 Sep 1.

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。

N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。

N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.

J Am Coll Cardiol. 2020 Jun 23;75(24):3085-3095. doi: 10.1016/j.jacc.2020.04.028. Epub 2020 Apr 16.

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.血管紧张素转换酶 2：SARS-CoV-2 受体和肾素-血管紧张素系统的调节剂：庆祝 ACE2 发现 20 周年。

Circ Res. 2020 May 8;126(10):1456-1474. doi: 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8.

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。

Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.意大利新冠肺炎死亡患者的病死率及特征

JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结

JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.血管紧张素转换酶2（ACE2）在严重急性呼吸综合征冠状病毒诱导的肺损伤中的关键作用。

Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267. Epub 2005 Jul 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Could Renin-Angiotensin System Inhibitors Be Protective From Severe COVID-19?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献